Product Details
Maxalt
Rizatriptan10 mg
Tablet
DIN/PIN/NPN
02240521
Manufacturer
Organon Canada Inc.
Formulary Listing Date
2012-05-29
Unit Price
21.4865
Amount MOH Pays
11.1150
Coverage Status
Off-Formulary Interchangeable Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
N02CC04
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02516756 | Rizatriptan | 11.1150 | 11.1150 |
02240521 | Maxalt | 21.4865 | 11.1150 |
02379678 | Mar-Rizatriptan | 11.1150 | 11.1150 |
02429241 | Jamp-Rizatriptan IR | 11.1150 | 11.1150 |
02380463 | Jamp-Rizatriptan | 11.1150 | 11.1150 |
02381702 | Act Rizatriptan | 11.1150 | 11.1150 |
02441144 | Auro-Rizatriptan | 11.1150 | 11.1150 |
02393476 | Apo-Rizatriptan | 11.1150 | 11.1150 |
LU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Migraine Drugs | Almotriptan
Naratriptan
Rizatriptan
Sumatriptan
For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g., acetaminophen, NSAIDs) and where the following information is provided:
Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e., more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP Drug Request Form: |